axicabtagene ciloleucel

This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts take centre stage as ASH18 comes to a close

Gilead also had new, two-year data to share on its already-marketed CAR-T Yescarta (axicabtagene ciloleucel) in r/r B-cell lymphoma that showed a sustained treatment effect, answering

Latest news

Gilead optimistic about Yescarta deal in UK

Yescarta (axicabtagene ciloleucel) and its rival CAR-T therapy Novartis’ Kymriah (Tisagenlecleucel-T) were granted European approved on the same day in relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Novartis’ CAR-T Kymriah gets green light in England

The rapid agreement on Kymriah is in stark contrast to NICE’s speedy rejection in draft guidance of Gilead/Kite Pharma’s rival CAR-T Yescarta (axicabtagene ciloleucel), which was approved
It’s a no for Yescarta, says NICE on heels of EU approval

The appraisal document for Yescarta (axicabtagene ciloleucel ) notes that the therapy “is not recommended, within its anticipated marketing authorisation, for treating relapsed or refractory diffuse large B-cell lymphoma or primary ... While Yescarta
MaxCyte gets green light for solid tumour cell therapy

The current generation of CAR-T therapies – namely Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) – use engineered T cells harvested from blood, which have to be expanded in
CAR-Ts Kymriah and Yescarta step closer to approval in Europe

However the EMA has been working on its own fast-track for the most important new drugs, the PRIority MEdicines (PRIME) scheme, and Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) are the

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

The European Medicines Agency: PRIME’d for access?

Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
Deal Watch January 2017

Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Client Services Director – Medical Education Agency – North West...: Salary TBC

Global Business Development Director – Health Education: excellent commission

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Manager / Account Director: Competative

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Account Director, Medical Education: Salary TBC

Medical Writer: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Associate Director: £75, 000-90, 000

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...